Pyrrolidine Derivative Targets Actin Cytoskeleton in MCF-7 Breast Cancer Cells

Abstract

Recent research has brought pyrrolidine derivatives into consideration for the development of anticancer drugs with high efficacy and low toxicity. Dr. Hansen’s lab at DePauw has synthesized a pyrrolidine derivative that demonstrated anticancer activity. However, there are many ways a compound can affect cancer cells. In this research, we decided to investigate the mechanism of action of this new compound, specifically on MCF-7 breast cancer cell line. Based on the results, we believe that there is a great likelihood that the pyrrolidine derivative can induce apoptosis (cell death) and disrupt cell movement in MCF-7 cells. In other words, these are strong indicators that this compound can inhibit both early and late-stage cancer cells.